The 2019 European Society for Medical Oncology (ESMO) Congress was held in Barcelona, Spain from 27 September to 1 October.

This podcast features Informa Pharma Intelligence analysts who closely covered key data presented at ESMO. Join them as they share their thoughts on some important themes from this year’s congress.

A full transcription of the discussion can be downloaded via the report PDF link above.

Topics covered in this podcast include:

• Mike Ramirez: Discussion of results for AMG 510 in colorectal cancer, as well as updates in first-line non-small cell lung cancer for Tecentriq, Opdivo, and Tagrisso (1:17)
  
  
• Zach McLellan: PARP inhibitors duel in ovarian cancer, including updates on Zejula, Lynparza, and veliparib (17:41)
  
  
• David Dahan: Phase II results for Debio 1143 combined with chemo-radiotherapy for patients with head and neck cancer and for tucatinib combined with Herceptin for patients with HER2+ colorectal cancer (27:47)
  
  
• Tara Hansen: Overview on Keytruda in triple-negative breast cancer, combination regimens in hepatocellular carcinoma, and new mechanism of action drugs in renal cell carcinoma (36:00)